New Federal Rules That Lower Barriers to Opioid Care Could Save Thousands of Lives
The two main medications that treat opioid use in the United States reduce overdose deaths by 50%. Yet fewer than one in 10 people with opioid use disorder (OUD) can access this kind of medical protocol, according to the Centers for Disease Control and Prevention (CDC). Fortunately, a new law and a new federal regulation […]
Characterizing Initiation, Use, and Discontinuation of Extended-Release Buprenorphine in a Nationally Representative United States Commercially Insured Cohort
Medications for opioid use disorder (MOUD) are evidence-based treatments that help people reduce or stop using opioids. However, high discontinuation rates of MOUD pose a barrier to reducing opioid-related overdoses. Extended-release buprenorphine (XR-BUP) is a relatively new MOUD, approved in late 2017, that has the potential to increase retention because of its monthly dosing schedule. Currently, there is […]
Achieving Value in Substance Use Disorder Treatment: Paying for What Works (and Not Paying for What Doesn’t): Workshop Summary
More than 100 policymakers, practitioners, and researchers discussed and debated how payment policy can promote evidence-based, cost-effective substance use disorder treatment, in a recent workshop hosted by the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV and HIV (CHERISH) and the Leonard Davis Institute of Health Economics at the University of […]
CHERISH Workshop Addresses an ‘Unfortunate Reality’ of the Addiction Treatment Industry
Funded by the National Institute on Drug Abuse and established in 2015, CHERISH is a five year collaboration of researchers from the Leonard Davis Institute of Health Economics (LDI) of the University of Pennsylvania, Weill Cornell Medical College, Boston Medical Center, and the University of Miami. Their work is focused on studying the health economics […]
Medications for Opioid Use Disorder: Who is Receiving Which Treatment?
In response to the growing opioid epidemic in the United States, there is an increased focus on expanding evidence-based treatment using medications prescribed for substance use disorder, especially medications that can be prescribed in outpatient settings including buprenorphine and naltrexone. The Surgeon General’s report on facing addiction in America describes substance use disorders as chronic illnesses requiring […]
Engage with CHERISH
Submit a Consultation Request or Contact Us to learn more about how CHERISH can support your research or policy goals.